[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK140430B - Analogifremgangsmåde til fremstilling af 3-aryloxy-3-phenylpropylaminer eller syreadditionssalte heraf. - Google Patents

Analogifremgangsmåde til fremstilling af 3-aryloxy-3-phenylpropylaminer eller syreadditionssalte heraf.

Info

Publication number
DK140430B
DK140430B DK688974AA DK688974A DK140430B DK 140430 B DK140430 B DK 140430B DK 688974A A DK688974A A DK 688974AA DK 688974 A DK688974 A DK 688974A DK 140430 B DK140430 B DK 140430B
Authority
DK
Denmark
Prior art keywords
phenylpropylamines
aryloxy
preparation
acid addition
addition salts
Prior art date
Application number
DK688974AA
Other languages
Danish (da)
English (en)
Other versions
DK140430C (de
DK688974A (de
Inventor
Bryan Barnet Molloy
Klaus Kurt Schmiegel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26625843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK140430(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from KR1019750000261A external-priority patent/KR800001009B1/ko
Publication of DK688974A publication Critical patent/DK688974A/da
Publication of DK140430B publication Critical patent/DK140430B/da
Application granted granted Critical
Publication of DK140430C publication Critical patent/DK140430C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK688974AA 1974-01-10 1974-12-30 Analogifremgangsmåde til fremstilling af 3-aryloxy-3-phenylpropylaminer eller syreadditionssalte heraf. DK140430B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/432,379 US4314081A (en) 1974-01-10 1974-01-10 Arloxyphenylpropylamines
KR1019750000261A KR800001009B1 (ko) 1975-01-09 1975-01-09 아릴옥시페닐프로필 아민류의 제조방법

Publications (3)

Publication Number Publication Date
DK688974A DK688974A (de) 1975-09-01
DK140430B true DK140430B (da) 1979-08-27
DK140430C DK140430C (de) 1980-01-21

Family

ID=26625843

Family Applications (1)

Application Number Title Priority Date Filing Date
DK688974AA DK140430B (da) 1974-01-10 1974-12-30 Analogifremgangsmåde til fremstilling af 3-aryloxy-3-phenylpropylaminer eller syreadditionssalte heraf.

Country Status (23)

Country Link
US (1) US4314081A (de)
JP (1) JPS5939418B2 (de)
AR (3) AR205577A1 (de)
AT (1) AT336000B (de)
BE (1) BE824255A (de)
BG (3) BG23212A3 (de)
CA (1) CA1051034A (de)
CH (1) CH609675A5 (de)
CS (1) CS189680B2 (de)
DD (1) DD118613A5 (de)
DE (1) DE2500110A1 (de)
DK (1) DK140430B (de)
ES (1) ES433720A1 (de)
FR (1) FR2257288B1 (de)
GB (1) GB1493961A (de)
IE (1) IE40346B1 (de)
NL (2) NL181654C (de)
PH (1) PH11652A (de)
RO (2) RO69763A (de)
SE (1) SE412906B (de)
SU (1) SU1005655A3 (de)
YU (3) YU36915B (de)
ZA (1) ZA7532B (de)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
JPS5283811A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Aryloxy phenyl propylamines and their salts
GB1570613A (en) * 1976-10-27 1980-07-02 Akzo Nv Biologically active tricyclic compounds and pharmaceutical compositions containing same
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
FR2455571A2 (fr) * 1979-02-15 1980-11-28 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments
DE3017812A1 (de) * 1980-05-09 1981-11-12 Merck Patent Gmbh, 6100 Darmstadt Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US4430319A (en) 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
US4692469A (en) * 1982-09-07 1987-09-08 Ciba-Geigy Corporation Propylamine derivatives
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
US4683235A (en) * 1985-02-25 1987-07-28 Eli Lilly And Company Analgesic method
US4594358A (en) * 1985-02-25 1986-06-10 Eli Lilly And Company Analgesic method
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US5149714A (en) * 1987-08-14 1992-09-22 Merrell Dow Pharmaceuticals Inc. Antidepressants
US5223540A (en) * 1987-10-22 1993-06-29 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US4971998A (en) * 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US4876282A (en) * 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
US5238959A (en) * 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
CA1337128C (en) * 1988-04-08 1995-09-26 David Wayne Robertson Propanamine derivatives
US5250571A (en) * 1988-11-14 1993-10-05 Eli Lilly And Company (S)-norfluoxetine in method of inhibiting serotonin uptake
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1228209B (it) * 1989-01-10 1991-06-05 Grato Magnone Procedimento per la preparazione di fluoxetina cloridrato.
FI81083C (fi) * 1989-03-03 1990-09-10 Orion Yhtymae Oy Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid.
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
JPH0375680U (de) * 1989-11-21 1991-07-30
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
US5250572A (en) * 1990-03-29 1993-10-05 Eli Lilly And Company (R)-norfluoxetine in method for occupying serotonin IC receptors
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5136079A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Regioselective synthesis
US5136078A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Synthesis of b-cyanohydrins
US5320825A (en) * 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
WO1993000811A1 (en) * 1991-07-01 1993-01-21 The General Hospital Corporation Invertebrate phenylethanolamine transporter and the use thereof
IL99316A (en) 1991-08-27 1995-03-15 Teva Pharma Production of fluoxetine and new intermediates
US5202319A (en) * 1991-09-23 1993-04-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
HU9202128D0 (en) * 1992-06-26 1992-10-28 Richter Gedeon Vegyeszet Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
EP0576766A1 (de) * 1992-06-29 1994-01-05 Novo Nordisk A/S Propanolamin-Derivate, ihre Herstellung und Verwendung
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ES2082723B1 (es) 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
ES2101650B1 (es) * 1995-06-29 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina.
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ES2101654B1 (es) * 1995-07-24 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2101655B1 (es) * 1995-07-28 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2103680B1 (es) * 1995-08-03 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina.
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
ES2103681B1 (es) * 1995-09-19 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina.
IT1283141B1 (it) * 1996-07-11 1998-04-07 Laporte Organics Francis S P A Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
AU737590B2 (en) * 1997-11-14 2001-08-23 N.V. Organon Use of mirtazapine for treating sleep apneas
US5936124A (en) * 1998-06-22 1999-08-10 Sepacor Inc. Fluoxetine process from benzoylpropionic acid
US6025517A (en) * 1998-08-03 2000-02-15 Sepracor Inc. Fluoxetine process from benzoylacetonitrile
AU2180400A (en) * 1999-01-13 2000-08-01 Eli Lilly And Company A pharmaceutical combination for the treatment of depression
FR2791345B1 (fr) * 1999-03-26 2001-05-04 Adir Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU3219800A (en) * 1999-03-29 2000-10-16 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
WO2001017521A1 (en) * 1999-09-03 2001-03-15 Eli Lilly And Company Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
EP1242362A4 (de) 1999-12-17 2003-07-09 Ranbaxy Lab Ltd Verfahren zur herstellung von fluoxetinhydrochlorid
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
EP1284729A4 (de) * 2000-04-13 2007-12-19 Mayo Foundation A-(beta)-42 senkende arzneimittel
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310251B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6313350B1 (en) 2001-01-31 2001-11-06 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310250B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form A of fluoxetine hydrochloride
US6258853B1 (en) 2001-01-31 2001-07-10 Grayson Walker Stowell Form a of fluoxetine hydrochloride
CH695982A5 (de) * 2001-03-06 2006-11-15 Lilly Co Eli Inhibitor der Monaminaufnahme.
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
EP2147679B1 (de) 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Zusammensetzungen für den Blut-Hirn-Schrankentransport
BR0211522A (pt) * 2001-07-31 2004-09-14 Upjohn Co Tratamento de dor crÈnica com 3-arilóxi-3-fenilpropanaminas
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
WO2003013480A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
CN101921267A (zh) * 2001-10-12 2010-12-22 阿泽范药品公司 β-内酰胺后叶加压素V1a拮抗剂
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
ES2287338T3 (es) * 2001-11-30 2007-12-16 Eli Lilly And Company Uso de inhibidores de recaptacion de norepinefrina para el tratamiento de trastornos de tics.
BR0213581A (pt) * 2001-12-11 2004-08-24 Lilly Co Eli Uso de um inibidor de recaptação de norepinefrina seletivo
WO2003102158A2 (en) * 2002-05-31 2003-12-11 The Forsyth Institute Methods for increasing bone density
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
US6846957B2 (en) * 2002-11-22 2005-01-25 Board Of Regents, The University Of Texas System Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
RS20050890A (en) * 2003-05-30 2007-12-31 Ranbaxy Laboratories Limited, Substituted pyrrole derivatives
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
DE602004024317D1 (de) 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
DE602004019118D1 (de) * 2003-09-17 2009-03-05 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
JP2007517050A (ja) * 2003-12-31 2007-06-28 アクタビス グループ フルータフェーラグ アトモキセチン製剤
US7893261B2 (en) * 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP1737473A4 (de) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Lithium-kombinationen und relevante verwendungen
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006037055A1 (en) * 2004-09-27 2006-04-06 Dr. Reddy's Laboratories Ltd. Synthesis of atomoxetine hydrochloride
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
US7399871B2 (en) * 2005-03-08 2008-07-15 Teva Pharmaceutical Industries Ltd. Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof
MX2007011255A (es) * 2005-03-14 2007-10-18 Teva Pharma Clohidrato de duloxetina puro.
WO2006102308A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1b antagonists
PE20061298A1 (es) 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
US7368477B2 (en) 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
EP1879875A1 (de) * 2005-04-22 2008-01-23 Wyeth Kristallformen von {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amin-hydrochlorid
GT200600165A (es) * 2005-04-22 2007-03-14 Derivados dihidrobenzofuranos y usos de los mismos
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
US7485754B2 (en) * 2005-07-08 2009-02-03 Apotex Pharmachem Inc. Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
AU2006269231A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
PL1910346T3 (pl) * 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
JP2009502807A (ja) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド 薬剤含有率の高い製剤および投与量形態
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
EP1838692A2 (de) * 2005-09-22 2007-10-03 Teva Pharmaceutical Industries Ltd Dnt-maleat und herstellungsverfahren dafür
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
CN1304360C (zh) * 2005-12-12 2007-03-14 天津大学 N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
WO2007086948A1 (en) * 2006-01-23 2007-08-02 Teva Pharmaceutical Industries Ltd. Dnt-fumarate and methods of preparation thereof
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
EP1998773A2 (de) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Neue therapeutische kombinationen zur behandlung von depression
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP1934197A2 (de) * 2006-05-23 2008-06-25 Teva Pharmaceutical Industries Ltd Duloxetin-hcl-polymorphe
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
AU2007274724B2 (en) * 2006-07-14 2012-07-26 Ranbaxy Laboratories Limited Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008026227A2 (en) * 2006-08-28 2008-03-06 Matrix Laboratories Ltd A process for the preparation of atomoxetine hydrochloride
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
CN101594878A (zh) 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
ITMI20061987A1 (it) 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
WO2008062473A1 (en) * 2006-10-31 2008-05-29 Cadila Healthcare Limited Process for preparing atomoxetine hydrochloride
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP3524248A1 (de) 2007-06-21 2019-08-14 VeroScience LLC Verfahren zur behandlung von metabolischen störungen und depressionen mit dopaminrezeptoragonisten
WO2009141833A2 (en) * 2008-04-17 2009-11-26 Ind-Swift Laboratories Limited An improved process for synthesizing highly pure atomoxetine
EP2288345B1 (de) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psychopharmazeutika
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
WO2011027359A2 (en) 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
EP2348120B1 (de) 2009-12-30 2014-06-11 Universität Wien Enzymatische Reduktion von 1-Phenylpropanon und Derivate davon
CN107007596A (zh) 2010-07-01 2017-08-04 阿泽凡药物公司 用于治疗创伤后应激障碍的方法
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
JP2014508187A (ja) 2011-03-17 2014-04-03 ルピン・リミテッド 選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
US20150190352A1 (en) 2012-07-31 2015-07-09 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret Anonim Sirketi Use of fluoxetine in animals
EA201590047A1 (ru) 2012-07-31 2015-09-30 Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. Применение флуоксетина для увеличения мясной и молочной продуктивности
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
MX2021005502A (es) 2014-03-28 2023-01-16 Azevan Pharmaceuticals Inc Composiciones y metodos para tratar enfermedades neurodegenerativas.
CN105777706B (zh) * 2014-12-25 2019-08-23 江苏恩华药业股份有限公司 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
EP3681871A4 (de) 2017-09-15 2021-05-26 Azevan Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von hirnverletzungen
CN114375191A (zh) 2019-07-19 2022-04-19 比奥克斯塞尔医疗股份有限公司 非镇静的右美托咪定治疗方案
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683742A (en) * 1951-02-23 1954-07-13 Searle & Co Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives
ES251290A1 (es) * 1958-08-21 1960-04-01 Parke Davis & Co Un procedimiento para la producciën de alcohilaminas arilsustituidas
US3132179A (en) * 1959-08-27 1964-05-05 Sterling Drug Inc Ethers of alpha-hydroxymethyl-beta-monocarbocyclic aryl ethyl amines and their preparation
US3253040A (en) * 1962-12-10 1966-05-24 Union Carbide Corp Process for the production of primary 3-hydrocarbyloxypropylamines

Also Published As

Publication number Publication date
DE2500110A1 (de) 1975-07-17
YU36915B (en) 1984-08-31
YU121481A (en) 1983-04-27
NL930108I1 (nl) 1993-10-18
JPS5939418B2 (ja) 1984-09-22
SE7500215L (de) 1975-07-11
AR205578A1 (es) 1976-05-14
ZA7532B (en) 1976-08-25
BG23212A3 (bg) 1977-07-12
DD118613A5 (de) 1976-03-12
CA1051034A (en) 1979-03-20
FR2257288A1 (de) 1975-08-08
CH609675A5 (de) 1979-03-15
CS189680B2 (en) 1979-04-30
SE412906B (sv) 1980-03-24
YU37308B (en) 1984-08-31
SU1005655A3 (ru) 1983-03-15
NL930108I2 (nl) 1994-08-16
YU121581A (en) 1983-04-27
JPS50101333A (de) 1975-08-11
AT336000B (de) 1977-04-12
RO70660B (ro) 1983-08-30
IE40346B1 (en) 1979-05-09
AR205633A1 (es) 1976-05-21
ATA10275A (de) 1976-08-15
RO70660A (ro) 1983-09-26
BG26192A3 (bg) 1979-02-15
BE824255A (fr) 1975-07-09
NL181654C (nl) 1987-10-01
FR2257288B1 (de) 1978-07-21
PH11652A (en) 1978-05-08
NL7500186A (nl) 1975-07-14
DK140430C (de) 1980-01-21
YU37307B (en) 1984-08-31
BG60761B2 (bg) 1996-02-29
DE2500110C2 (de) 1987-06-11
AR205577A1 (es) 1976-05-14
IE40346L (en) 1975-07-10
ES433720A1 (es) 1976-12-01
NL181654B (nl) 1987-05-04
US4314081A (en) 1982-02-02
RO69763A (ro) 1982-02-26
DK688974A (de) 1975-09-01
YU3275A (en) 1982-06-18
GB1493961A (en) 1977-12-07
AU7683674A (en) 1976-06-24

Similar Documents

Publication Publication Date Title
DK140430B (da) Analogifremgangsmåde til fremstilling af 3-aryloxy-3-phenylpropylaminer eller syreadditionssalte heraf.
DK140840B (da) Analogifremgangsmåde til fremstilling af benzimidazolderivater eller syreadditionssalte deraf.
DK129446B (da) Analogifremgangsmåde til fremstilling af fenoxyhydroxypropylaminer eller syreadditionssalte heraf.
DK352875A (da) Fremgangsmade til fremstilling af 5,9-betadisubstituerede 2-tetrahydrofurfuryl-6,7-benzomorphaner eller syreadditionssalte heraf
DK137188C (da) Analogifremgangsmaade til fremstilling af 2-tetrahydrofurfuryl-6,7-benzomorphaner eller syreadditionssalte heraf
DK131287B (da) Analogifremgangsmåde til fremstilling af 2-phenylimino-imidazolidiner eller syreadditionssalte deraf.
DK138893B (da) Analogifremgangsmåde til fremstilling af 1-(indolyl-3-alkyl)-4-ureido-piperidiner eller -thioureido-piperidiner eller syreadditionssalte deraf.
DK441875A (da) Fremgangsmade til fremstilling af 2-phenyliminoimidazolidiner eller syreadditionssalte deraf
DK136859B (da) Analogifremgangsmåde til fremstilling af tertiære aminoalkylfenylætere eller syreadditionssalte deraf.
DK139575B (da) Analogifremgangsmåde til fremstilling af 2-aminomethylen-1-indanon-forbindelser eller syreadditionssalte deraf.
DK138427B (da) Analogifremgangsmåde til fremstilling af amider af apovincamin- og desoxyvincaminsyre eller syreadditionssalte heraf.
DK138491B (da) Analogifremgangsmåde til fremstilling af N-(1-cyclohexyl-3-pyrrolidinyl)-benzamider eller syreadditionssalte deraf.
DK137953B (da) Analogifremgangsmåde til fremstilling af amidoximderivater eller syreadditionssalte deraf.
DK139574B (da) Analogifremgangsmåde til fremstilling af terpeno-phenoxy-alkylaminer eller syreadditionssalte deraf.
DK140590B (da) Analogifremgangsmåde til fremstilling af 4-cyclopropylmethylenoxy-3-chlorphenyleddikesyre eller salte heraf.
DK131857B (da) Analogifremgangsmåde til fremstilling af 4-hydroxymethyl-1-phthalazonderivater eller syreadditionssalte deraf.
DK138943B (da) Analogifremgangsmåde til fremstilling af substituerede dibenzocyclohepten-carboxamider eller syreadditionssalte deraf.
DK135800B (da) Analogifremgangsmåde til fremstilling af (L)-1-(4-hydroxyphenoxy)-2-hydroxy-3-isopropylamino-propan eller syreadditionssalte deraf.
DK137757B (da) Analogifremgangsmåde til fremstilling af pyridylpiperaziner eller syreadditionssalte deraf.
DK138227B (da) Analogifremgangsmåde til fremstilling af substituerede xanthon-2-carboxylsyreforbindelser.
DK134014B (da) Analogifremgangsmåde til fremstilling af cycloalkyllactamimider eller syreadditionssalte deraf.
DK140259B (da) Analogifremgangsmåde til fremstilling af 1-(L-(-)-omega-amino-alfa-hydroxyalkanoyl)-kanamyciner eller syreadditionssalte deraf.
DK140431B (da) Analogifremgangsmåde til fremstilling af et N2-dansyl-L-arginin-derivat eller syreadditionssalte deraf.
DK129164B (da) Analogifremgangsmåde til fremstilling af 3-alkyl-5-aryloxymethylisoxazoler eller syreadditionssalte deraf.
DK135500C (da) Fremgangsmade til fremstilling af alfa1-tert.butylaminomethyl-4-hydroxy-m-xylen-alfa1,alfa3-diol eller syreadditionssalte deraf

Legal Events

Date Code Title Description
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1993 00028, 930621

CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1993 00028, 930621

PUP Patent expired